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Complement-Independent, Peroxide-Induced
Antibody Lysis of Platelets in HIV-1-Related
Immune Thrombocytopenia
Affinity purification of anti-platelet GPIIIa Ab from
CIC’s of these patients has revealed a high affinity IgG1
(Karpatkin et al., 1995) reactive against a specific se-
quence within the GPIIIa protein corresponding to resi-
dues 49–66 (Nardi et al., 1997). The presence of anti-
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New York University School of Medicine GPIIIa49-66 Ab correlates inversely with platelet count
(r 0.71) and induces severe thrombocytopenia in mice550 First Avenue
New York, New York 10016 (Nardi et al., 1997) (mouse GPIIIa is 83% homologous
with human GPIIIa, and macrophages have Fc receptors
for human IgG1). Murine thrombocytopenia can be pre-
vented or reversed with GPIIIa49-66 peptide (Nardi etSummary
al., 1997), as well as anti-idiotype blocking Ab (Nardi
and Karpatkin, 2000).Immunologic thrombocytopenia is seen commonly in
HIV-1 infection. The pathogenesis of this problem has Anti-GPIIIa49-66 Ab CICs can be removed from serum
by centrifugation (Nardi et al., 1997), suggesting thebeen unclear, but it is associated with circulating im-
mune complexes that contain platelet membrane presence of particulate platelet membrane fragments
within the CIC. This report confirms the presence ofcomponents and anti-platelet membrane GPIIIa49-66
IgG antibodies. These antibodies cause acute throm- these fragments in HIV-1-ITP serum. The CICs from
HIV-1-ITP patients contain platelet membrane receptorbocytopenia when injected into mice. We now show
that purified anti-GPIIIa49-66 causes platelet fragmen- antigen GPIIIa as well as GPIIb and GPIb, and we show
that platelet fragments can be induced in vitro and intation, in vitro in the absence of complement, and in
vivo in wild-type and C3-deficient mice. The mecha- vivo with anti-GPIIIa49-66 Ab. We further report that Ab-
mediated fragmentation is complement independentnism of complement-independent platelet lysis is shown
to be caused by the antibody-induced generation of and occurs via a novel mechanism involving the genera-
tion of hydrogen peroxide by stimulation of an NADPHH202, as indicated by in vitro experiments with inhibi-
tors of reactive oxygen species, and in vivo studies oxidase pathway in platelets.
carried out with p47phox-deficient mice. Thus, a novel
mechanism of immunologic platelet clearance is de- Results
scribed in which an anti-platelet IgG causes platelet
fragmentation via the induction of reactive oxygen Detection of Platelet Glycoproteins in PEG-IC’s
species. of HIV-1-ITP Patients
Previous results have shown increased serum concen-
Introduction tration of CIC in patients with HIV-1-ITP and that these
CIC’s contain Ab specific for GPIIIa49-66. We confirmed
Immunologic thrombocytopenia is a common complica- these results in the population studied by demonstrating
tion of HIV-1 infection (Jost et al., 1988; Morris et al., a 5.5-fold greater protein concentration of PEG-IC’s de-
1982; Murphy et al., 1987). Kinetic studies on platelet rived from 46 HIV-1-ITP patients compared to 22 normal
survival strongly suggest that early-onset HIV-1-ITP is control subjects. PEG-IC size was also measured in a
secondary to increased peripheral destruction of plate- similar cohort of patients. There was a 2-fold greater size
lets, whereas patients with AIDS are more likely to have in 35 HIV-1-ITP patients compared to 15 control subjects,
decreased platelet production (Najean and Rain, 1994). as determined by forward light scatter (p  0.01).
Patients with early-onset HIV-1-ITP have a thrombocy- In a previous report, the loss of 75% of anti-
topenic disorder that is indistinguishable from classic GPIIIa49-66 activity in PEG-IC following centrifugation
autoimmune thrombocytopenia (ATP), seen predomi- at 100,000 g for 1 hr suggested the possible presence
nantly in females (Karpatkin, 1997; Morris et al., 1982; of platelet membrane fragments in the IC’s (Nardi et al.,
Ratnoff et al., 1983; Savona et al., 1985; Walsh et al., 1997). This was supported by immunoblot of the IC’s
1984). However, HIV-1-ITP is different from classic ATP with mAb’s versus platelet membrane GPIIIa and GPIb,
in that HIV-1-ITP patients have a male predominance which demonstrated molecular fragments of these re-
with markedly elevated platelet-associated IgG, IgM, ceptors (Figure 1A). This observation was confirmed
complement proteins C3 and C4, and the presence of employing an ELISA analysis of IC samples from 35
circulating serum immune complexes (CIC’s) composed patients with HIV-1-ITP compared to 15 control subjects
of the same (Savona et al., 1985; Walsh et al., 1984). employing a FITC-mAb against GPIIb (data not shown).
Past studies have revealed that these complexes con-
tain anti-platelet integrin GPIIIa (3) Ab (Karpatkin et Antibody Specific for GPIIIa49-66 Induces Platelet
al., 1995), and its anti-idiotype blocking Ab (Nardi and Fragmentation In Vitro
Karpatkin, 2000), as well as other Ab’s and their anti- The presence of platelet membrane antigens in
idiotypes (Karpatkin et al., 1988, 1992a; Yu et al., 1986). PEG-IC’s of HIV-1-ITP patients raises the possibility that
anti-GPIIIa49-66 Ab may be inducing fragmentation. To
investigate this possibility, we determined whether affin-4Correspondence: simon.karpatkin@med.nyu.edu
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Figure 1. In Vitro Platelet Fragmentation In-
duced by Anti-GPIIIa49-66 Ab
(A) Immunoblot of PEG-IC of control and
HIV-1-ITP patients employing anti-GPIIIa,
anti-GPIb, and control mouse monoclonal
Ab, MoPC. CTL refers to control.
(B) Flow cytometry of platelet in vitro particle
formation. Gel-filtered platelets were labeled
with anti-GPIIb-FITC monoclonal Ab, washed,
and then treated with various agents: buffer,
control IgG, and patient anti-GPIIIa49-66 for
4 hr at 37C. Three panels represent: CTL,
buffer alone; CTL IgG, IgG isolated from con-
trol PEG-IC; and PT IgG, IgG isolated from
HIV-1-ITP patient PEG-IC. X axis refers to flu-
orescence, y axis to forward scatter. Numbers
in left upper quadrant refer to the percentage
of Ab-induced particles with decreased fluo-
rescence attributed to platelet fragmenta-
tion. A highly-reactive anti-GPIIIa49-66 IgG is
shown.
(C) Distribution of percentage of platelet par-
ticle formation in control versus HIV-1-ITP
versus ATP patients at 1 hr incubation. Re-
sults shown for IgG isolated from PEG-IC’s
of 12 control, 16 HIV-1-ITP, and 5 ATP pa-
tients. Box Plot. Mean is shown by the solid
black box; median by the horizontal line in
the large open box; 25th and 75th percentiles
by the lower and upper border of the large
open box from which spread of the data from
the position of the median can be assessed.
Whiskers include 99% of a Gaussian distri-
bution.
ity-purified anti-GPIIIa49-66 Ab could induce platelet Specificity of Anti-GPIIIa49-66
for Platelet Fragmentationfragmentation in vitro in the absence of serum or com-
plement. Figure 1B shows the flow cytometric analysis Five different anti-GPIIIa mAb’s with different specifici-
ties for GPIIIa (Liu et al., 1995), and an anti-GPIb mAbof one such experiment in which anti-GPIIb-FITC-
labeled platelets shifted their fluorescence intensity and failed to induce platelet particle formation (Table 1). In
striking contrast, an affinity-purified anti-GPIIIa49-66distribution from the RUQ to the lower end of the LUQ,
indicating platelet fragmentation and diminished fluo- rabbit polyclonal Ab was effective at inducing platelet
particle formation, albeit at an 8-fold higher concentra-rescence intensity, presumably via the loss of mem-
brane GPIIb fluorescence as well as the production of tion than patient IgG (Figure 2). Preimmune rabbit IgG
was inactive.smaller particles.
Analysis of Platelet Fragmentation Induced Exposure of Membrane Fragment Phosphatidylserine
by Anti-GPIIIa49-66 and Thrombin-Generating Capacity
Optimum platelet particle formation occurred at 4 hr, by Anti-GPIIIa49-66
with 25 g/ml anti-GPIIIa49-66 Ab. Platelet particle for- Since platelet activation/vesicle formation is associated
mation by anti-GPIIIa49-66 Ab was concentration de- with inside-outside membrane exposure as reflected by
pendent, with an optimum Ab concentration of 40 g/ml phosphatidylserine exposure, attempts were made to
for fragmentation. Ab-induced platelet particle forma- measure this reaction via binding of the reaction prod-
tion was also temperature dependent. Inactivity at 4C ucts to Annexin-V. Figure 3A demonstrates increased
permitted overnight storage of samples prior to analysis Annexin-V binding with time, with all of the activity in the
by flow cytometry, whenever necessary. supernatant obtained after centrifugation of the platelet/
platelet particle mixture at 15,000 g for 1 hr at room
temperature, indicating that fragments contain phos-Induction of Platelet Fragmentation in HIV-1-ITP
versus Classic ATP Patients phatidylserine.
The exposure of phosphatidylserine on membranesPlatelet particle formation was compared in HIV-1-ITP
patients, ATP patients, and control subjects. There was generally leads to thrombin generation, since it provides
a catalytic surface for binding of plasma coagulation pro-approximately 5-fold greater platelet particle formation
in HIV-1-ITP patients compared to control subjects or teins to the surface. We therefore analyzed Ab-induced
platelet particles for their ability to generate thrombin.ATP patients (Figure 1C).
Peroxide-Induced Ab Lysis of Platelets
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Table 1. Specificity of Ab-Induced Platelet Particle Formation
% Platelet Particles
0 Hrs 2 Hrs 4 Hrs
PEG-IC IgG
CTL 0.80 0.55 0.50
PT 0.87 11.1 19.7
MoAb Anti-GPIIIa
LK6-55 0.83 0.76 0.50
CG4 0.81 0.55 0.81
LK7r 0.75 0.54 0.63
LK3r 0.75 0.53 1.20
LK4-55 0.91 0.70 0.62
MoAb Anti-GPIb
Anti-Ib 0.69 0.68 0.71
Figure 2. Comparison of Rabbit versus Patient Anti-GPIIIa49-66-
Ab concentration, 25 g/ml Induced Platelet Particle Formation
Preimmune rabbit and patient control IgG reactivity are cited under
CTL. Affinity-purified rabbit anti-GPIIIa49-66 IgG or isolated patient
anti-GPIIIa49-66 IgG was incubated with gel-filtered platelets atFigure 3B clearly demonstrates thrombin generation
varying concentrations of Ab and analyzed by flow cytometry as in
after 4 hr of exposure of Ab employing a chromogenic Figure 1B.
assay (1 of 2 similar experiments).
Platelet Fragmentation Induced by F(ab)2 be induced in vivo by F(ab)2 at 75% the efficacy of intact
and Fab Fragments IgG, (10 versus 13.5% respectively, with 1% for control
Platelet particle formation could be induced with F(ab)2 F(ab)2 fragments, n  6). Thus, clearance of opsonized
fragments, indicating that complement was unlikely to platelets and fragments can take place in the absence
be involved in this reaction. Of interest was the positive of Ab binding to Fc or C3 complement receptors on
result obtained with 2-fold molar equivalent Fab frag- phagocytic cells, perhaps by other phagocytic scaven-
ments, albeit at60% the effective platelet particle for- ger mechanisms (Fadok et al., 1992; Tait and Smith,
mation of F(ab)2 fragments (p  0.05, Student’s t test), 1999).
suggesting the possibility that dimerization of GPIIIa
could play a role. Induction of Platelet Fragmentation via Anti-
GPIIIa49-66 Is Mediated by the Generation
Induction of Thrombocytopenia and Platelet of Peroxide and GPIIIa49-66 Specific Antibodies
Fragmentation in Complement-Deficient Numerous attempts to elucidate the mechanism(s) of
C3(	/	) Mice Ab-induced platelet particle formation were unsuccess-
The ability to generate platelet particles in vitro, in the ful. These included inhibitors of anerobic and aerobic
absence of the Fc domain of anti-platelet GPIIIa49-66, glycolysis (3 mM 2-deoxyglucose, 10 mM NaAz), micro-
strongly suggested that platelet particle formation was tubules (2 mM colchicine, 0.2 mM vinblastine), microfila-
independent of complement fixation. Nevertheless, ments (10M cytochalasin D), calpain (100M calpasta-
complement deposition on cell membranes can induce tin, 5 g/ml leupeptin), apoptosis (100 M general
membrane vesiculation (as well as cell lysis), and it is caspases [FK-011] and caspases 1 and 3), proteases
possible that complement may play a role in platelet (5 g/ml leupeptin, 2 mM PMSF, 5 M SBTI, 5000 g/ml
fragmentation in vivo. We therefore attempted to induce aprotinin, 4 mM EDTA), Ca2
 (4 mM EDTA, 100 M
thrombocytopenia in C3-deficient and wild-type mice. BAPTA-AM), and various intracellular signaling kinases:
Figures 4A and 4B show similar levels of thrombocyto- 2 M wortmannin (PI3Kinase), 200 M staurosporine
penia induction and platelet particle formation in both (phospholipid/Ca2
-dependent protein kinase), 40 M
wild-type and C3(	/	) mice, indicating that C3 comple- H-7 (serine/threonine kinase), and 200 M PDC980598
ment is not required for platelet fragmentation and (MAPKinase). However, a recent report by Lerner and
thrombocytopenia in this model. coworkers (Wentworth et al., 2000) provided evidence
that all Ab’s are capable of inducing peroxide formation
from an assortment of Ag’s. This reaction required theInduction of Thrombocytopenia and Platelet
Fragmentation with F(ab)2 Fragments generation of singlet 102 via irradiation with UV or visible
light. This is followed by Ab-Ag induced reduction of 102Induction of thrombocytopenia in complement-deficient
mice indicated that in vivo thrombocytopenia was not to 0	2 (superoxide) with consequent generation of H202,
which could be neutralized with catalase. We thereforedue to complement-mediated cell clearance, but likely
to be due to clearance of opsonized platelets as well studied the effect of catalase on platelet particle forma-
tion induced by either human or rabbit anti-GPIIIa49-66as platelet fragmentation. The role of these 2 mecha-
nisms was analyzed by measuring the contribution of and noted that it could inhibit the reaction with either
Ab, but in the absence of UV/light irradiation (Figure 5A).F(ab)2 fragments versus intact IgG. Thrombocytopenia
could be induced in Balb/c mice in the absence of the This suggested a different mechanism, namely that 102
could be generated by a specific cellular generatingFc domain of IgG but at 40% the efficiency of intact IgG
(n  6). Similarly, platelet particle formation could also system such as the NADH/NADPH oxidase system. This
Cell
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Figure 3. Phosphatidylserine Exposure and
Thrombin Generation from Platelet Particles
Induced by Control and Patient Anti-
GPIIIa49-66 Isolated from PEG-IC’s
(A) Phosphatidylserine exposure. Open bars
refer to Annexin-V binding of entire platelet
suspension; black bars refer to similar bind-
ing of supernatant platelet particles following
centrifugation at 15,000g  1 hr, n  3, SEM
is given.
(B) Thrombin generation. Platelet micropar-
ticles were induced by Anti-GPIIIa49-66 Ab
at 0 and 4 hrs. The 15,000  g supernatant
containing platelet microparticles was added
to defibrinated plasma in the presence of
thrombin chomophore S2238 and CaCl2 for 3
min and the developed color read spectro-
photometrically at 410 nm. Typical of 2 differ-
ent experiments.
hypothesis was tested with the use of diphenyleneio- Additional studies revealed Ab concentration depen-
dence with saturation at 10–20 g/ml (n  2, data notdonium (DPI), an inhibitor of NADH/NADPH oxidase, as
well as other flavoprotein oxidases. Figure 5A demon- shown).
The GPIIIa49-66 specificity of this reaction wasstrates inhibition by DPI as well as superoxide dismutase
(SOD) in a similar manner as catalase. Similar results addressed by employing the experimentally raised rab-
bit anti-GPIIIa49-66 Ab as well as 5 anti-GPIIIa mAb’swere obtained with the human Ab (data not shown).
Three other oxidase inhibitors failed to inhibit Ab-medi- with different specificity for GPIIIa. Similar fragmenta-
tion and oxidation results for both time and concentra-ated platelet particle formation: 20 M indomethacin
against cyclooxygenase, 200 M allopurinol against tion-dependent variables were obtained with rabbit
anti-GPIIIa49-66 and clinically derived platelet Ab. All 5xanthine oxidase, and 200 M L-N-monomethylarginine
against NO synthetase (data not shown). anti-GPIIIa mAb’s that had no effect on platelet fragmen-
tation also had no effect on oxidation of platelet DCFH.Further proof that platelets were generating peroxide
following incubation with anti-GPIIIa49-66 was obtained
using an intracellular fluorescent probe, DCFH, that Induction of Platelet Fragmentation by Thrombin
Does Not Require Reactive Oxygen Speciesmeasures peroxide oxidation. Platelets were loaded
with DCFH, treated with anti-GPIIIa49-66 Ab, and perox- Thrombin is known to induce platelet fragmentation.
Similar experiments were designed to test whetheride generation assayed by measurement of fluores-
cence. Figure 5B demonstrates increased fluorescence thrombin-induced fragmentation was also dependent
on the generation of reactive oxygen species. In contrast(shift to the right of the x axis) and platelet particle
formation (downward shift on the y axis) for both 1 and to the anti-GPIIIa49-66 Ab, thrombin-induced platelet
fragmentation was not inhibited by catalase, DPI, or4 hr of incubation with Ab. In 4–5 experiments, the in-
crease over baseline oxidation for 1 and 4 hr was 8.1  superoxide dismutase (Figure 5C). Similarly, the intracel-
lular dye DCFH was not oxidized by thrombin. Mean1.3 and 7.8  0.7 fold, respectively. The increase in the
platelet particle formation was 1.9  0.5 and 6.5  1.7 fluorescence for platelets alone, platelets plus 1 M
H202, or platelets plus 2.5 g/ml thrombin were 33  11,fold, respectively, and blocked by catalase. There was
a lag period between particle formation and peroxide 304 2, and 23 6 respectively (n 3) following 4 hr of
incubation at 37C. Platelet fragmentation for platelets,generation, as indicated by the greater increase in parti-
cle formation between 1 and 4 hr compared to oxidation. platelets plus H202, and platelets plus thrombin was 5%,
Figure 4. Effect of Anti-GPIIIa49-66 Ab on
Platelet Count and Platelet Particle Formation
in Control and Complement-Deficient Mice
(A) B6129 control and C3	/	 deficient mice
were injected ip with 25 g of control (open
square) or anti-GPIIIa49-66 Ab and platelet
count monitored at various time intervals. WT
refers to wild-type; Mut to C3	/	 mice, n 
5 for each group, SEM is given.
(B) Percentage of platelet particles was moni-
tored at 4 hr. Ctl refers to control IgG; Pt refers
to anti-GPIIIa 49-66.
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Figure 5. Generation of Peroxide and Effect of Peroxide Inhibitors, Catalase, Diphenyleneiodonium (DPI), and Superoxide Dismutase (SOD)
with Platelet Particle Formation Induced by Anti-GPIIIa49-66 Ab or Thrombin
(A) Gel-filtered platelets were preincubated with inhibitor or buffer for 15 min prior to the addition of rabbit anti-GPIIIa49-66 Ab or control IgG.
C refers to control nonimmune IgG (similar results with control plus highest inhibitor concentration employed), IS refers to rabbit anti-GPIIIa49-66
immune serum. Bars labeled 2, 3, and 4 after bar 1 refer to doubling concentrations of inhibitor (50 g/ml catalase, 5 nM/ml DPI, and 12.5
g/ml SOD), n  4, SEM is given.
(B) Generation of peroxide by anti-GPIIIa49-66 at 1 hr (panels A, B, and C) and 4 hr (panels D, E, and F). Platelets were loaded with the
intracellular dye, DCFH-DA, and then treated with buffer (panels A and D), control IgG (panels B and E), or human anti-GPIIIa49-66 (panels C
and F).
(C) Effect of peroxide inhibitors on thrombin-induced platelet particle formation. Gel-filtered platelets were preincubated with inhibitors as in (A)
and then treated with 1 g/ml thrombin for 4 hr. Bars refer to doubling concentrations, n  4.
14%, and 17% respectively (1 of 2 experiments with ference noted between patient F(ab)2 fragment in wild-
type mice and its IgG preparation in p47phox(	/	) mice.similar results).
Further, anti-GPIIIa49-66 Ab failed to produce any plate-
let particle formation in p47phox(	/	) mice, comparedInduction of Thrombocytopenia and Platelet
to 26% platelet particle formation in wild-type mice (Fig-Fragmentation in NADPH-Deficient
ure 6B). These data indicate that platelet particle for-(p47phox[	/	]) Mice
mation is induced by H202 damage generated byInhibition of platelet fragmentation by inhibitors of H2O2
Ab-induced activation of the NADPH oxidase pathwaygeneration suggested that platelets contain a peroxide
and that platelet fragmentation contributes to plateletgenerating pathway, namely the NADPH oxidase system
clearance.present in granulocytes/phagocytes (Segal et al., 2000).
In vivo experiments were therefore performed in
p47phox(	/	) mice deficient in the p47 component of Electron Microscopy of Platelet Fragmentation
Induced by Anti-GPIIIa49-66 Abthe phagocytic oxidase complex necessary for H202 gen-
eration via the NADPH oxidase pathway. Figure 6A dem- Figure 7 demonstrates the dramatic progressive platelet
damage induced by anti-GPIIIa49-66 antibody at 1 andonstrates that thrombocytopenia induced in p47 phox
(	/	) mice by anti-GPIIIa49-66 Ab was only 40% of 4 hr of incubation. Ab-damaged platelets develop breaks
in their membrane, swelling, and release of cytoplasmicthat obtained with wild-type C57/BL6 mice, with no dif-
Cell
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Figure 6. Effect of Anti-GPIIIa49-66 Ab on
Platelet Count and Platelet Particle Formation
in Control C57BL/6 and p47phox(	/	) Mice
Control C57BL/6 (open square, closed circle,
closed square) or p47phox(	/	) (open circle)
mice were injected ip with 25 g of intact
anti-GPIIIa49-66 or 16 g of its F(ab)2 frag-
ment and platelet count and percent platelet
particles monitored at 2 and 4 hr. (A) Platelet
count. (B) Percent platelet particles. n  6–8
for each group, SEM is given.
fragments. At 4 hr, there was a 6-fold greater incidence induced platelet fragmentation by peroxide inhibitors,
catalase, superoxide dismutase, and DPI, as well as Ab-of fragmented platelets treated with anti-GPIIIa49-66
compared to control IgG (30% versus 5%) in 12 sections induced intracellular oxidation of DCFH in vitro, and by
the inability of anti-GPIIIa49-66 to induce microparticleanalyzed in each group. Conversely, there was a 5-fold
increase in intact undamaged platelets in control versus formation and thrombocytopenia in p47 phox (	/	)
mice. Specificity is shown by similar results obtained withanti-GPIIIa49-66 treated platelets (62% versus 13%). At
1 hr, platelets had cytoplasmic-like material attached to an experimentally raised rabbit Ab versus GPIIIa49-66,
with lack of effect for other anti-GPIIIa Ab’s directedthe external surface of their membranes (Figures 7A–
7C). Cytoplasmic contents leaked out of the platelet against other epitopes as well as an anti-GPIb Ab.
Membrane shedding or “microparticle formation” is athrough gaps in the membranes and adhered to the
outer surface but the granules are preserved (Figures normal property of cells grown in culture (Armstrong et
al., 1988; Beaudoin and Grondin, 1991; Mallat and et al.,7B and 7C). This was confirmed by measuring lactic
dehydrogenase release into the media of platelet sus- 1999), as well as cells undergoing apoptosis (Aupeix et
al., 1997; Segundo et al., 1999). Platelet microparticlepensions treated with Ab. No release was noted with
control Ab at 1 and 4 hr, whereas anti-GPIIIa49-66- formation is enhanced by numerous pathophysiologic
conditions such as agonist-induced platelet activationtreated platelets released 175 and 537 units/L, respec-
tively, in the 10,000  g supernatant (representative of (Shcherbina and Remold-O’Donnell, 1999; Sims et al.,
1989; Wolf et al., 1999), complement-induced platelet2 experiments). Some platelets show vacuolization. At
4 hr, most platelets showed signs of cellular injury (cyto- lysis (Sims et al., 1988), autoimmune thrombocytopenia
(Jy et al., 1992b; Khan et al., 1975; Zucker-Franklin andplasmic denudation as well as fragmentation). Many
were swollen and others showed partial or almost total Karpatkin, 1977), and other conditions (Abrams et al.,
1990; George et al., 1986; Holme et al., 1994, 1997;disintegration of their cell membrane (Figures 7E, 7F,
and 7H). Dense and other granules were unaffected. Hughes et al., 2000; Jansen et al., 1997; Kelton et al.,
1996; Lee et al., 1994; Miyamoto et al., 1998; NieuwlandClumping of cellular debris with platelet fragments was
also seen (Figure 7H). No such changes were noted with et al., 2000; Warkentin et al., 1994). Platelet micropar-
ticles induced by platelet agonists have been reportedcontrol IgG-treated platelets (Figure 7D). The superna-
tant collected from the centrifuged platelet samples to contain GPIIb/GPIIIa, GPIb (Sims et al., 1988, 1989),
CD9 (Inngjerdingen et al., 1999), P-selectin (Abrams etconsisted mostly of cell debris with occasional degener-
ating platelets (data not shown). Of interest is the obser- al., 1990; Inngjerdingen et al., 1999; Sims et al., 1988),
and Factor V (Sims et al., 1988) and to require Ca2
vation that a minority of platelets (perhaps young plate-
lets [Karpatkin, 1969]) appear resistant to this Ab (Weidmer et al., 1990), calpain (Fox et al., 1991; Weidmer
et al., 1990; Wolf et al., 1999; Yano et al., 1993), caspasedamage (Figures 7G and 7I).
3 (Shcherbina and Remold-O’Donnell, 1999), and intact
GPIIb/GPIIIa (Gemmell et al., 1993) for their formation.Discussion
Whether platelet microparticles with potential bioactive
properties contribute to the pathophysiology of diseaseThese data reveal a new pathophysiologic mechanism
for platelet destruction (fragmentation) by an autoanti- or are a secondary consequence has not been resolved.
For example, platelet microvesicles can generate throm-body specific for a platelet GPIIIa49-66 epitope. The
mechanism is complement independent and involves bin (Sims et al., 1989), bind to fibrinogen (Holme et al.,
1998b; Sims et al., 1989), coaggregate platelets (Holmeperoxide damage generated by an NADPH oxidase
pathway in platelets. Complement independence is et al., 1998b), adhere to subendothelium (Owens et al.,
1992), and stimulate monocyte-endothelial cell adhe-shown by Ab-induced microparticle formation with
F(ab)2 fragments in vitro, and by Ab-induced thrombo- sion via upregulation of adhesion molecules for both
cells (Barry et al., 1998). It has been proposed that plate-cytopenia and microparticle formation in C3 (	/	) mice,
in vivo. Peroxide damage is shown by inhibition of Ab- let microvesicles exert a protective hemostatic effect
Peroxide-Induced Ab Lysis of Platelets
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Figure 7. Electron Microscopy of Damaged Platelets Ttreated with Anti-GPIIIa49-66 Ab
(A) Patient sample at 1 hr showing platelets with a fuzzy material attached to the outer surface of the cell membranes (dotted arrows). Gaps
are noted in the cell membranes with leakage of cytoplasmic content (arrows). These areas are demonstrated at higher magnification in (B)
and (C)
(E) Patient sample at 4 hr showing degenerating platelets and disintegration of the cell membrane (arrow). Swollen platelet (F), platelet
fragments (H), and occasional normal platelets (G and I) are also seen. None of these changes were present in IgG controls at 4 hr (D). Original
magnifications: (A), (D–I): 4,000. (B) 50,000. (C) 40,000.
in ATP patients (Jy et al., 1992a), may influence the A recent morphologic analysis of microparticles in-
duced by heparin-dependent Abs revealed the elabora-development of atherosclerosis (Mallat and et al., 1999;
Nomura et al., 1995), and may contribute to the develop- tion of membrane-bound vesicles released from swell-
ings on the platelet body or from pseudopods ofment of thrombosis in heparin-induced thrombocytope-
nic purpura (HITP) (Warkentin et al., 1994). Patients with activated platelets (Hughes et al., 2000). Similar particles
can be produced by thrombin (Shcherbina and Remold-HIV-1 infection have a higher incidence of platelet micro-
particles (Holme et al., 1998a) and a higher incidence of O’Donnell, 1999; Sims et al., 1989; Wolf et al., 1999).
However, the platelet “microparticles” produced by anti-thrombotic thrombocytopenic purpura (TTP) (Leaf et al.,
1988). GPIIIa49-66 are different in that they are induced by
Cell
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al., 1992b). Fab fragments were prepared by papain digestion ofmembrane damage secondary to peroxide generation
IgG as described (Karpatkin et al., 1992b) and verified by SDS-rather than platelet activation. Nevertheless, they are
PAGE.similar with respect to phosphatidylserine exposure and
ability to induce thrombin generation. The difference Immune Complexes
is supported by biochemical as well as morphologic Circulating immune complexes (CIC’s) were isolated from serum
evidence: (1) microparticle formation could not be inhib- by polyethylene glycol precipitation (PEG-IC) (Nardi and Karpatkin,
2000; Walsh et al., 1984). Precipitates were dissolved in one fifthited by two anti-caspase inhibitors (FK-011, DEVD-fmk),
their serum volume in 0.01 M PBS (pH 7.4).two calpain inhibitors (calpastatin, leupeptin), or extra-
cellular and intracellular calcium chelators (EDTA and
ImmunoblotBAPTA-AM, respectively), which inhibit platelet micro-
Twenty-five micrograms of PEG-IC were run on 10% SDS-PAGE,
particle formation induced by platelet agonists (Fox et transferred to nitrocellulose paper, and immunoblotted with mouse
al., 1991; Gemmell et al., 1993; Shcherbina and Remold- monoclonal Ab’s against GPIIIa (LK7r), GPIb (1b10), and an irrele-
O’Donnell, 1999; Weidmer et al., 1990; Wolf et al., 1999; vant Ab (MOPC) for 2 hr, followed by washing and blocking with
5% BLOTTO. Ab binding was detected with a sheep anti-mouseYano et al., 1993); (2) thrombin-induced platelet forma-
IgG coupled to horesradish peroxidase (F(ab)2 specific) for 2 hr,tion did not require the generation of reactive oxygen
followed by washing as above, and detection with luminol (NEN,species and was not inhibited by catalase, DPI, or super-
Boston, MA).
oxide dismutase; and (3) EM studies reveal cell swelling,
membrane disruption with release of cellular contents, Isolation of IgG and IgM from Immune Complexes
and apparent cellular debris, as well as isolated vesicles. IgG and IgM were isolated and purified as described (Karpatkin et
al., 1995). In brief, polyethylene glycol (PEG)-ICs were applied to aThe ability of an Ab to induce platelet fragmentation by
protein A affinity column (Sigma-Aldrich). The bound complex wasreactivity with a specific epitope on platelet membrane
washed with PBS and eluted with 0.1 M glycine buffer (pH 2.5). TheGPIIIa via elaboration of platelet generated peroxide
eluted material was applied to an acidified sephadex G-200 gelis unique. The sequence specifity of anti-GPIIIa Ab in
filtration column (Amersham Pharmacia Biotech) preequilibrated
inducing platelet fragmentation by the peroxide-depen- with the same elution buffer. Effluents of the IgG peak were isolated,
dent mechanism is supported by our finding that 5 other neutralized, dialyzed against PBS, and applied to a rabbit anti-IgM
affinity column (ICN Pharmaceuticals, Inc.) prepared from Affi-Gelanti-GPIIIa mAb’s against at least 4 different regions of
10 (BioRad). The flow-through material was free of contaminatingGPIIIa (Liu et al., 1995), as well as a mAb against GPIb,
IgM by immunoblot and ELISA. Effluents of the IgM peak werefailed to induce platelet fragmentation. Sequence speci-
isolated, neutralized, dialyzed against PBS, and applied to an anti-ficity was confirmed using an anti-peptide antibody
Fc receptor affinity column to remove rheumatoid factor. The flow-
against GPIIIa49-66, which gave a similar platelet frag- through IgM was devoid of rheumatoid factor, as determined by
mentation histogram to patient IgG, albeit at 8-fold inability to bind to a second Fc column. Fc fragments were prepared
by papain digestion (Karpatkin et al., 1992b) and affinity purified onhigher concentration with similar peroxide-dependent
a staphylococcal protein A column; the acid eluate was verified byrequirement. These observations suggest the possibility
SDS-PAGE and was coupled to Affi-Gel 10.of a conformational change induced at a specific region
of GPIIIa which is capable of activating a peroxide-gen-
Affinity Purification of Anti-Platelet IgG
erating pathway in platelets. Antiplatelet IgG was affinity purified with 108 platelets fixed with
Our observations on platelet destruction and micro- 2% paraformaldehyde for 2 hr at room temperature, followed by
particle formation with IgG as well as F(ab)2 fragments, overnight gentle rocking at 4C, then acid elution and neutralization,
as described (Karpatkin et al., 1995). The IgG subclass, determinedin both wild-type and C3(	/	) mice, as well as abroga-
by radial immunodiffusion (The Binding Site), was IgG1 with both ktion of this effect in p47 phox(	/	) mice, strongly indi-
and l light chains.cate that platelet destruction can be via a platelet frag-
mentation mechanism induced by peroxide generation
Affinity Purification of Anti-Platelet GPIIIa49-66
with clearance by other than classic Fc or complement Peptide GPIIIa49-66, CAPESIEFPVSEARVLED (synthesized by Qual-
receptors. ity Controlled Biochemicals, Hopkinton, MA), was coupled to an
affinity column with the heterobifunctional cross-linker sulfo-succin-
Experimental Procedures imidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate as recom-
mended by the manufacturer (Pierce Chemical Co.; cross-links the
Human Population resin with NH2-terminal cysteine of the peptide), and was incubated
Patient sera were obtained from 46 early-onset HIV-1-infected with 0.4 ml of platelet affinity-purified IgG overnight at 4C. The
thrombocytopenic patients without AIDS, 12 control subjects column was then washed, eluted at pH 2.5, and neutralized as de-
(healthy laboratory personnel), and 5 classic ATP patients. scribed (Karpatkin et al., 1995). The affinity-purified anti-platelet
GPIIIa49-66 was nonreactive in buffer alone by flow cytometry, dem-
onstrating absence of detectable microparticles or human plateletMice
Female BALB/c, B6129, and C57BL/6 mice were obtained from Ta- debris.
conic Farms. C3(	/	) X B6129 background were mice generated
by Dr. Harvey Colton, Northwestern University Medical School, Chi- Induction of Platelet Particles
cago, IL (Circolo et al., 1999) and kindly supplied by Drs. Susan Gel-filtered normal platelets were prepared from platelet-rich
Boackle and Michael Holers at the University of Colorado Health plasma obtained from blood collected in 0.38% sodium citrate utiliz-
Science Center. NADPH-deficient mice (p47phox (phagocyte ing a sepharose 2B column preincubated with Tyrode’s buffer
oxidase)(	/	) X C57BL/6 were kindly provided by Dr. Harry L. Ma- (pH 7.4). 1  107 gel-filtered platelets/ml were either unlabeled or
lech, NIAID, Bethesda, MD (Jackson et al., 1995). labeled with an anti-GPIIb-FITC monoclonal Ab (mAb) (3B2) (Varon
and Karpatkin, 1983) or an anti-GPIIIa-FITC mAb (Ancell, Bayport,
MN), 10 g/ml for 30 min at 4C, centrifuged at 1000 g  6 min atF(ab)2 and Fab
F(ab)2 fragments were prepared from purified IgG by pepsin diges- room temperature, and resuspended in Tyrodes buffer. Ten microli-
ters of unlabeled or FITC-labeled platelets (107/ml) were then incu-tion as described (Karpatkin et al., 1992b), and were shown to be
free of Fc fragments by SDS-PAGE as well as ELISA (Karpatkin et bated with 15 l of thrombin (final concentration, 1–2.5 g/ml) or
Peroxide-Induced Ab Lysis of Platelets
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affinity-purified anti-GPIIIa49-66 (5–40 g/ml), and 75 l Tyrodes logicals, Inc (Reamstown, PA) employing KLH-conjugated GPIIIa49-66
with 4 booster injections 21–77 days post primary injection of 500 g.buffer for 0–4 hr at 37C and then stored in an ice bucket prior to
measurement of percentage of platelet particles by flow cytometry.
Further particle formation is arrested at 0C (see below). For throm- Electron Microscopy
bin experiments, CaCl2 (0.9 mM) and MgCl2 (0.5 mM) were added Platelets were suspended in an equal volume of 2% Bacto-Agar
to the Tyrodes buffer. and fixed in 3% glutaraldehyde in 0.1 M sodium cacodylate buffer.
For mouse in vivo studies, blood was collected from the orbital Samples were washed twice in buffer, post-fixed with 1.5% osmium
sinus with Unopettes (Becton-Dickinson) or by cardiac puncture tetroxide and rewashed 2 times with buffer. Samples were then
into a heparinized syringe after anesthesizing mice with metafane dehydrated and embedded in Eponate-12 resin. Thin sections were
(Schering-Plough Animal Health, Union, NJ). Platelet-rich plasma cut in a Reichert Ultracut 5 ultramicrotome, counterstained with
was prepared and incubated with mAb anti-mouse CD41-FITC (In- uranyl acetate and lead citrate, and anlyzed using a Zeiss EM-10
tegrin IIb chain, Pharmingen, San Deigo, CA) for 30 min at 4C and electon microscope.
then assayed directly by flow cytometry.
Materials
Assay of Platelet Particle Formation All reagents were obtained from Sigma (St. Louis, MO) unless other-
Both fluorescent-labeled or unlabeled percentage of platelet parti- wise designated. PDC980598 (MAPKinase inhibitor) was obtained
cles were measured by flow cytometry, employing a FACScan (Bec- from Research Biochemicals Inc., Natick, MA. Anti-caspases 1 and
ton-Dickinson, Montain View, CA). Similar results were obtained by 3 and BAPTA-AM were obtained from Molecular Probes, Eugene,
both methods. Debris and dead cells were excluded using scatter OR. MAb’s against platelet GPIIIa (LK6-55, LK7r, LK3r, LK4-r5, and
gates. Only cells with low orthogonal light scattering were included CG4, and GPIIb (3B2) were produced in our laboratory (Liu et al.,
in the sorting gates. Gates were adjusted for control platelets by 1995; Varon and Karpatkin, 1983). MAb against GPIb (1b10) was
exclusion of other blood cells. Fluorescent-labeled intact platelets a gift from Dr. Zaverio Ruggeri, Scripps Research Institute, La Jolla,
were monitored in the right upper quadrant (RUQ) with the y axis CA. Thrombin substrate S2238 was obtained from DiaPharma Group.
measuring forward-scatter and the x axis measuring fluorescence.
For nonfluorescent cells, the y axis measured forward scatter and Acknowledgments
the x axis measured side scatter. A shift in fluorescent or nonfluores-
cent particles from RUQ to LUQ and LLQ reflected percentage of Supported by NIH grants HL-13336 and DA-04315 (S.K.), The Doro-
platelet particle induction of 10,000 counted platelets/particles. thy and Seymour Weinstein Platelet Research Fund (S.K.), NIH grant
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assayed by flow cytometry. the flow cytometry analysis.
Phosphatidylserine was measured by solid phase assay, em-
ploying streptavidin-labeled plastic microtiter plates (Boehringer- Received March 19, 2001; revised July 23, 2001.
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